TY - JOUR
AU - Hemmelgarn B.
AU - Levin A.
AU - Kasiske B.
AU - Wheeler D.
AU - Wanner C.
AU - Groop P.
AU - Agarwal R.
AU - Thomas M.
AU - Fioretto P.
AU - Perkovic Vlado
AB - <p>
The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.
</p>

AD - George Institute for Global Health, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, New South Wales, Australia. Electronic address: vperkovic@georgeinstitute.org.au.<br/>Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.<br/>Department of Medicine, University of Padova, Italy.<br/>Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Interdisciplinary Chronic Disease Collaboration, Calgary, Alberta, Canada; Libin Cardiovascular Institute and Institute of Public Health, University of Calgary, Calgary, Alberta, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.<br/>Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada; BC Provincial Renal Agency, Vancouver, British Columbia, Canada; Centre for Health Evaluation and Outcomes Research, St. Paul's Hospital, Vancouver, British Columbia, Canada.<br/>Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Melbourne, Victoria, Australia.<br/>Renal Division, University Hospital of Wurzburg, Wurzburg, Germany.<br/>Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota, USA.<br/>University College London, London, UK.<br/>Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; Folkhalsan Institute of Genetics, Folkhalsan Research Center, Helsinki, Finland; Diabetes and Obesity Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland; Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: per-henrik.groop@helsinki.fi.
AN - 27884312
BT - Kidney Int
CN - [IF]: 8.563
DP - NLM
ET - 2016/11/26
J2 - Kidney international
LA - Eng
LB - AUS<br/>R&M<br/>FY17
M1 - 6
N1 - Perkovic, Vlado<br/>Agarwal, Rajiv<br/>Fioretto, Paola<br/>Hemmelgarn, Brenda R<br/>Levin, Adeera<br/>Thomas, Merlin C<br/>Wanner, Christoph<br/>Kasiske, Bertram L<br/>Wheeler, David C<br/>Groop, Per-Henrik<br/>Conference Participants<br/>United States<br/>Kidney Int. 2016 Dec;90(6):1175-1183. doi: 10.1016/j.kint.2016.09.010.
N2 - <p>
The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.
</p>

PY - 2016
SN - 1523-1755 (Electronic)<br/>0085-2538 (Linking)
SP - 1175
EP - 1183
ST - Kidney Int.Kidney Int.
T2 - Kidney Int
TI - Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
VL - 90
Y2 - FY17
ER -